$EMR has released earnings for Q4 and the full year 2024, announcing a robust performance with underlying sales growth of 6% and an adjusted EPS of $5.49, reflecting a strong operational execution. Risks remain with ongoing challenges in the discrete markets, while opportunities include a significant backlog of $7.2 billion and a strategic proposal to acquire the remaining shares of AspenTech, aiming for portfolio transformation. Future guidance suggests continued mid-single-digit growth in 2025. 📈💰 Full details at valueverge.com/EMR.
